Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine and Rituximab in CLL
NCT00072007Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jun 2002
- Primary completion
- Mar 2003
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in chronic lymphocytic leukemia (CLL), sponsored by Swiss Group for Clinical Cancer Research. Started Jun 2002; status: completed.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00072007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072007.